The Gaithersburg, Maryland-based firm intends to use the proceeds for general corporate purposes, including working capital and product development.
T2 said that the panel will be commercially available in Europe in Q3, and added that it is in the midst of completing a pivotal trial in preparation of a submission to the FDA.
The companies will combine OpGen's Acuitas Rapid Test for Pathogen ID and Thermo Fisher's new mid-throughput real-time PCR system.
An OpenArray panel designed to simultaneously test for 17 viruses and 13 bacteria and protozoa was able to detect pathogens from human blood donor samples with an accuracy of about 95 percent.
The loan from the European Investment Bank will go toward the development of Stat-Dx's diagnostic platform for detecting infectious pathogens, such as meningitis.
The firm is in the process of sequencing phage genomes as well as bacterial genomes before and after phage infection, in order to develop antimicrobials.
The funding will go toward completing the development of the company's point-of-care platform for distinguishing bacterial from viral infections.
The firm has immediate access to $800,000 in previously restricted cash, and an additional $10.8 million in capital through new convertible notes.
Researchers described a vancomycin-resistant Enterococcus infection transmitted from a liver donor to recipient, ruling out hospital-acquired infection with genomics.
The firm said that its metagenomic sequencing-based service provides a broad scope of pathogen testing for people with chronic medical conditions.
CNBC reports that Amazon invested in the startup Grail as it sees an opportunity for its cloud computing company in genomics.
Lawrence Krauss writes at Slate that science is needed for good public policy and should not be ignored.
Researchers are working on re-making the yeast genome from scratch, according to the Associated Press.
In Cell this week: functional profiling of Plasmodium genome, a self-inactivating rabies virus, and more.